We demonstrated that SCD1 and FADS2 could be potential biomarkers to predict or diagnose aggressive breast cancer, and the SCD1 or FADS2 expression is positively related to infiltration of immune cells in tumor microenvironment. Here, SCD is linked to breast carcinoma.